OncoSec Medical Incorporated (ONCS) Shares Up 9.5%
OncoSec Medical Incorporated (NASDAQ:ONCS) shot up 9.5% during mid-day trading on Thursday . The company traded as high as $2.25 and last traded at $2.20. 1,592,700 shares traded hands during trading, an increase of 86% from the average session volume of 858,228 shares. The stock had previously closed at $2.01.
A number of brokerages have issued reports on ONCS. Maxim Group reissued a “buy” rating and set a $5.00 target price on shares of OncoSec Medical in a research note on Thursday, October 26th. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of OncoSec Medical in a research note on Thursday, November 9th. Finally, ValuEngine raised shares of OncoSec Medical from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 9th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $5.33.
OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). equities analysts forecast that OncoSec Medical Incorporated will post -0.86 EPS for the current year.
WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/oncosec-medical-incorporated-oncs-shares-up-9-5/1722379.html.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.